A Critical Review: Psychophysical Assessments of Diabetic Retinopathy
Overview
Authors
Affiliations
Diabetic retinal disease remains a leading cause of vision loss despite currently available screening methods, ocular treatments, and efforts to control metabolic dysfunction. It is now understood that diabetes damages the entire retina and the cellular components of the neurovascular unit. Multiple studies have demonstrated impairment of various aspects of retinal function across the spectrum of retinopathy severity. Here we review these tests, the principles underlying their use, clinical data from multiple publications, the strengths and limitations of the studies, and prospects for their application to understand the pathophysiology of diabetic retinal disease and monitor its response to therapy. We focus on visual acuity, contrast sensitivity, color vision, visual field, and dark adaptation and their use to understand the pathophysiology of diabetic retinopathy and as potential endpoints for clinical trials.
Tang V, Symons R, Fourlanos S, Guest D, McKendrick A Ophthalmic Physiol Opt. 2024; 45(1):77-88.
PMID: 39400905 PMC: 11629852. DOI: 10.1111/opo.13394.
Clinical Evidence of a Photoreceptor Origin in Diabetic Retinal Disease.
Rajagopal R, Kern T Ophthalmol Sci. 2024; 5(1):100591.
PMID: 39328824 PMC: 11426126. DOI: 10.1016/j.xops.2024.100591.
Glassman A, Elmasry M, Baskin D, Brigell M, Chong V, Davis Q Ophthalmol Sci. 2024; 4(5):100519.
PMID: 38881606 PMC: 11179417. DOI: 10.1016/j.xops.2024.100519.
Li S, Tao Y, Yang M, Zhao H, Si M, Cui W Front Endocrinol (Lausanne). 2024; 15:1286736.
PMID: 38455651 PMC: 10919144. DOI: 10.3389/fendo.2024.1286736.
Achromatic and chromatic contrast discrimination in patients with type 2 diabetes.
Tsai L, Chen C, Hou C, Liao K Sci Rep. 2023; 13(1):7420.
PMID: 37156848 PMC: 10167204. DOI: 10.1038/s41598-023-34407-1.